Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
← catalyst calendarNCT07421700 · readout in 473 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With Astellas Pharma Inc.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
132estimated
Sites
153
Countries
Australia, China, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-11 | actual | When the study began enrolling |
| Primary completion | 2027-12-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-05 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urothelial Cancer
- Advanced/Metastatic Urothelial Cancer
- Urothelial Carcinoma
Interventions
- Biological: PF-08634404 — also filed as SSGJ-707
- Biological: Enfortumab Vedotin — also filed as PF-08046042, ASG-22CE, PADCEV
Primary outcomes
what the primary-completion date above is the date OFConfirmed Objective Response Rate (ORR) by investigator
measured Up to approximately 3 years
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Through 90 days after the last study intervention; Up to approximately 3 years
Number of participants with dose limiting toxicity (DLT) in Part 1 of Cohort B
measured Through 90 days after the last study intervention; Up to approximately 3 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed